The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

The second possibility is that Covid has now settled into a rut, which will see it become progressively milder until it ultimately becomes akin to the common cold. Chin-Hong says that this would make ...

For decades, lab-made antibodies have been used to support patients fighting specific diseases. These treatments have become ...

The spike protein of the coronavirus, or SARS-CoV-2, binds to ACE2, a receptor on the host cells, which allows the virus to enter the cells and infect it. Binding is the first step for infection, and ...

Renowned computational biologist Janet Thornton discusses the potential of protein structure understanding in developing new ...

It started as a respiratory illness—or so everyone thought. But it quickly became apparent that SARS-CoV-2, the virus that ...

Five years after SARS-CoV-2 first surfaced in Wuhan, China, researchers are still trying to understand long COVID. In this ...

The Kyushu University researchers studied the genetic information of the novel coronavirus, which was published in January, and set their sights on a “spike protein” shaped like a protuberance.

The video shows two segments: one featuring commentary about a substance binding to the coronavirus surface, followed by a narration discussing vaccine spike protein structure and antibody responses.

Boehringer will leverage ExpressionEdits' Genetic Syntax Engine which generates optimized introns to increase protein expression.

The video shows two segments: one featuring commentary about a substance binding to the coronavirus surface, followed by a narration discussing vaccine spike protein structure and antibody responses.

But it quickly became apparent that SARS-CoV-2, the virus that causes COVID-19, was so much more ... which the virus infiltrates using a spike protein on its outer membrane.